Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program

Share Article

The Drug Information Association (DIA) today announced the creation of its Clinical Safety and Pharmacovigilance Certificate Program.

News Image
Our new Clinical Safety and Pharmacovigilance Certificate Program addresses the practical and theoretical aspects of the conduct of pharmacovigilance.

The Drug Information Association (DIA) today announced the creation of its Clinical Safety and Pharmacovigilance Certificate Program. This is the third program developed by DIA, which also offers a certificate program in clinical research and project management. DIA’s Clinical Safety and Pharmacovigilance Certificate Program focuses on topics related to:

  •     Pre- and postmarketing clinical safety and pharmacovigilance
  •     Risk management strategies
  •     Safety inspections
  •     Signal detection and data mining
  •     Medical approaches in diagnosis and management of ADRs
  •     Drug safety surveillance and epidemiology

DIA is an established, recognized training authority for professionals who work in all areas of the biopharmaceutical industry. Its certificate program features world-class faculty and small interactive courses that include case studies, simulations, and other activities that expand learning, while offering continuing education credits.

“Our new Clinical Safety and Pharmacovigilance Certificate Program addresses the practical and theoretical aspects of the conduct of pharmacovigilance, with emphasis on the concepts and themes that create effective processes, as well as the basic tenets of global regulatory compliance with safety principles,” says DIA Worldwide Executive Director Paul Pomerantz, MBA, CAE.

Enrollment is free. Fees for each course vary based on length. For more information, visit the Clinical Safety and Pharmacovigilance Certificate Progra m page or contact Laura Parker at 215-442-6101 or Laura.Parker(at)diahome(dot)org.

About the Drug Information Association (DIA)
As a nonprofit member-driven association, DIA serves more than 30,000 professionals involved in the biopharmaceutical industry, academia, research organizations and governmental bodies worldwide. DIA fosters innovation of products, technologies, and services to improve health and well being worldwide by providing indispensible forums to exchange vital information and discuss current issues, delivering customized learning experiences, building, maintaining, and facilitating trusted relationships with and among individuals and organizations that drive and share DIA values and mandates, and providing a multidisciplinary neutral environment, respected globally for integrity and relevancy. DIA is led by its volunteer Board of Directors and executive management team, has headquarters in Horsham, PA, USA, and offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China. For more information, visit http://www.diahome.org or call 215-442-6100.

Contact:
Joe Krasowski
DIA
215-293-5812
Joe.Krasowski(at)diahome(dot)org

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joe Krasowski
Visit website

Media